SINOVAC and Eurofarma Establish Strategic Vaccine Partnership in Brazil Witnessed by President Lula

BEIJING, May 13, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced the signing of a strategic vaccine cooperation agreement with Eurofarma, a leading Brazilian pharmaceutical company. The signing ceremony was witnessed by Brazilian President Luiz Inácio Lula da Silva.

Under the terms of the agreement, the two organizations will establish a Sino-Brazilian vaccine manufacturing platform. This initiative is designed to facilitate the localized production of various vaccines, targeting supply requirements for the Brazilian market and extending reach to other nations in the Global South.

Strengthening Public Health Infrastructure The signing was attended by high-level officials, including Brazil's Minister of Health, Alexandre Padilha; Chief of Staff, Rui Costa; and Minister of Foreign Affairs, Mauro Vieira. SINOVAC leadership present included Chairman, President, and CEO Weidong Yin; Vice President Weining Meng; and Director of International Organizations (LATAM), Cintia Lucci.

Minister Padilha noted the historical significance of the partnership, referencing SINOVAC's critical role in Brazil's pandemic response. He emphasized that the ongoing collaboration and SINOVAC's sustained investment in the region serve as a testament to the deepened technical and institutional trust between the two entities.

During the event, President Lula highlighted the strategic nature of the Brazil-China relationship, noting that China remains an essential partner. He welcomed the expansion of Chinese industrial and health-related investments within Brazil.

Commitment to Research and Regional Stability On May 13, a delegation led by Minister Padilha conducted a formal visit to the SINOVAC Vaccine Quality Research Center in Beijing for a technical tour and high-level exchange. The delegation was received by SINOVAC's executive leadership, including Chairman and CEO Weidong Yin. The visit focused on reviewing the milestones achieved through localized vaccine production in Brazil and the technical standards maintained across SINOVAC's research and manufacturing facilities.

SINOVAC's long-term strategy in Latin America is built on deep-tier partnerships in markets such as Brazil, Chile, and Colombia. These collaborations extend beyond supply to include vaccine R&D, clinical research, and the establishment of localized production capabilities. Notable examples include the joint research and manufacturing initiatives with the Butantan Institute in Brazil and the Pontifical Catholic University of Chile, which have positioned SINOVAC as a primary vaccine provider within the regional health ecosystem.

Long-term Outlook Internationalization remains a core component of SINOVAC's long-term growth strategy. By prioritizing Brazil and the wider Latin American region, the Company intends to transition from a supplier model to a deeply integrated partner, investing in frontier biotechnologies and broader healthcare infrastructure to support regional health security.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.